Advertisement

April 16, 2020

SCAI Position Statement Addresses Training for Treatment of Adult Congenital Heart Disease

April 16, 2020—The Society for Cardiovascular Angiography and Interventions (SCAI) announced it has released a position statement on adult congenital cardiac interventional training, competencies, and organizational recommendations. The statement, which is endorsed by the Adult Congenital Heart Association, was published by Jamil A. Aboulhosn, MD, et al online in Catheterization and Cardiovascular Interventions.

SCAI noted that the number of adults with congenital heart disease (CHD) in the United States now exceeds the number of pediatric patients. CHD is the most common congenital abnormality and occurs in approximately 0.8% of all live births.

According to SCAI, the statement focuses on three major areas: eligibility for training, training environment and duration of training, and procedural volume. It identifies four main training backgrounds for candidates and individual determination of training period(s).

As outlined by SCAI, key recommendations include:

  • During an adult CHD interventional training curriculum, trainees should participate as a primary operator or first assistant in at least 150 adult CHD catheterization cases (100 should be interventional procedures)
  • Training of future specialists for this specific population should be delivered by multidisciplinary teams that combine adult and pediatric expertise in a collaborative approach
  • Multisociety collaboration should be engaged to help establish and maintain competency standards for physician

Dr. Aboulhosn, chair of the writing group, commented in the SCAI announcement, “The writing group included representatives from the areas of adult congenital cardiology, pediatric interventional cardiology, and structural interventional cardiology. The recommendations made have wide applicability to trainees and established interventionalists from a variety of clinical and training backgrounds. In addition, the statement affirms the importance of institutional and team staffing, procedures, and processes to ensure delivery of high quality invasive cardiac care.” Dr. Aboulhosn is Director, Ahmanson/UCLA Adult Congenital Heart Disease Center in Los Angeles, California.

Advertisement


April 16, 2020

FDA Issues Guidance on Conduct of Clinical Trials of Medical Products During the COVID-19 Emergency

April 16, 2020

Proximo Medical Named Commercialization Partner for Elucid Bioimaging